CZC-25146 hydrochloride

CAS No. 1330003-04-7

CZC-25146 hydrochloride( —— )

Catalog No. M19921 CAS No. 1330003-04-7

CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 101 Get Quote
10MG 178 Get Quote
25MG 296 Get Quote
50MG 443 Get Quote
100MG 645 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CZC-25146 hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.
  • Description
    CZC-25146 is a selective LRRK2 inhibitor with IC50 of 4.76 nM/6.87 nM for wild type LRRK2 and G2019S LRRK2 respectively.
  • In Vitro
    CZC-25146 (0.01-5 μM; 7 days) does not cause cytotoxicity in human cortical neurons, nor blocking neuronal development.CZC-25146 (0.01-5 μM; 2 days) potently attenuates G2019S LRRK2-mediated toxicity in primary rodent neurons in a concentration-dependent manner with an EC50 of ~100 nM.CZC-25146 (0.06-1000 nM) rescues LRRK2 G2019S-induced neurite defects in primary human neurons in a dose-dependent manner.CZC-25146 (14.3 and 28.6 μM; 48 h) markedly reduces The mutant AAT encoded by the Z allele (ATZ) polymer load and restores AAT secretion in iPSC-Hepatocyte, without compromising cell viability. Cell Cytotoxicity Assay Cell Line:Human cortical neurons Concentration:0.01, 0.1, 1 and 5 μM Incubation Time:7 days Result:Did not cause cytotoxicity in human cortical neurons at concentrations below 5 μM over a seven-day treatment in culture, nor did it block neuronal development.
  • In Vivo
    CZC-25146 (1 mg/kg for i.v.; 5 mg/kg for p.o.; single dosage) exhibits relatively good pharmacokinetic properties and an extensive distribution throughout animal body following intravenous injection into mice.CZC-25146 (250 mg/kg; p.o.; 14 days) reduces the ATZ polymer levels in over expressing human polymeric ATZ mice. Animal Model:Male CD-1 mice Dosage:1 mg/kg for i.v.; 5 mg/kg for p.o.Administration:i.v. and p.o.; single dosage Result:Pharmacokinetic Parameters of CZC-25146 in male CD-1 mice.Animal Model:Genetically modified male mice (6 weeks; over expressing human polymeric ATZ) Dosage:250 mg/kg Administration:p.o.; 14 days Result:Dramatically and reproducibly reduced the ATZ polymer levels with an overall reduction from 60% in the control group to 37%
  • Synonyms
    ——
  • Pathway
    Autophagy
  • Target
    LRRK2
  • Recptor
    LRRK2 (G2019S) LRRK2 (WT)
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1330003-04-7
  • Formula Weight
    525
  • Molecular Formula
    C22H26ClFN6O4S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 15 mg/mL
  • SMILES
    Cl.COc1cc(ccc1Nc1ncc(F)c(Nc2ccccc2NS(C)(=O)=O)n1)N1CCOCC1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ramsden N et al. Chemoproteomics-based design of potent LRRK2-selective lead compounds that attenuate Parkinson's disease-related toxicity in human neurons. ACS Chem Biol. 2011 Oct 21;6(10):1021-8.
molnova catalog
related products
  • EB-42486

    EB-42486 is an effective and highly selective inhibitor of G2019S-LRRK2 with an IC50 < 0.2 nM.

  • HG-10-102-01

    HG-10-102-01 is an inhibitor of leucine-rich repeat kinase 2 (LRRK2 IC50 of 20.3 nM).

  • LRRK2-IN-1

    A potent LRRK2 inhibitor with IC50s of 13 nM/6 nM for wild-type/G2019S mutant LRRK2 repectively (0.1 mM ATP in the assay).